The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
Open accessAbstract
Purpose: We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin alone in patients with malignant pleural mesothelioma (MPM). Patients and Methods: Eligible patients with histologically proven advanced MPM, not pretreated with chemotherapy, WHO performance status (PS) 0 to 2, and adequate hematological, renal, and hepatic function were randomly assigned to receive cisplatin 80 mg/m 2 IV on day 1, alone (arm A) or combined with raltitrexed 3 mg/m 2(arm B). In patients with measurable disease, response was monitored using the Response Evaluation Criteria in Solid Tumors criteria. Health related quality of life (HRQOL) was measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 and Lung Module (QLQ-LC13). Results: Two hundred fifty patients were randomized: 80% male; median age, 58 years; and WHO PS, 0, 1, 2 in 25, 62, and 13% of cases, respectively. There were no toxic deaths. The main grade 3 or 4 toxicities observed were neutropenia and emesis, reported twice as often in the combination arm. Among 213 patients with measurable disease, response rate was 13.6% (arm A) versus 23.6% (arm B; P = .056). No difference in HRQOL was observed on any of the scales. Median overall and 1-year survival in arms A and B were 8.8 (95% CI, 7.8 to 10.8) v 11.4 months (95% CI, 10.1 to 15), respectively, and 40% v 46%, respectively (P = .048). Conclusion: A combination of raltitrexed and cisplatin improves overall survival compared with cisplatin alone. This study confirms that a combination of cisplatin and an antifolate is superior to cisplatin alone in patients with MPM, without harmful effect on HRQOL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Self-citationTNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
International Union against Cancer
(1959) · Journal of the Faculty of Radiologists · doi:10.1016/s0368-2242(59)80060-9 · Cited by 1,220
The European mesothelioma epidemic
Peto, J., Decarli, A., Vecchia, C. L., Levi, F., & Negri, E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690105 · Cited by 891
Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Rougier, P., Adenis, A., Ducreux, M., de Forni, M., Bonneterre, J., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00072-1 · Cited by 751
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Self-citationModified RECIST criteria for assessment of response in malignant pleural mesothelioma
Byrne, M. J., & Nowak, A. K. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh059 · Cited by 645
Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P. E., & Giaccone, G. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.145 · Cited by 543
Self-citationJackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, H., Judson, I. R., & Lr, H. (1991) · PubMed · Cited by 357
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
Byrne, M. J., Davidson, J. A., Musk, A. W., Dewar, J., van Hazel, G., Buck, M., de Klerk, N. H., & Robinson, B. W. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.25 · Cited by 334
Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., & Zurlo, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.121 · Cited by 246
Self-citationBerghmans, T., Paesmans, M., Lalami, Y., Louviaux, I., Luce, S., Mascaux, C., Meert, A. P., & Sculier, J. P. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00180-0 · Cited by 190
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
van Haarst, J. M. W., Baas, P., Manegold, C., Schouwink, J. H., Burgers, J. A., de Bruin, H. G., Mooi, W. J., van Klaveren, R. J., de Jonge, M. J. A., & van Meerbeeck, J. P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600118 · Cited by 159
Self-citationHigh-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
Solheim, Ø. P., Sæter, G., Finnanger, A., & Stenwig, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.200 · Cited by 139
Fizazi, K. S., Doubre, H., Chevalier, T. L., Riviere, A., Viala, J., Daniel, C., Robert, L., Barthélemy, P., Fandi, A., & Ruffiè, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.123 · Cited by 132
van Klaveren, R. V., Aerts, J., de Bruin, H. D., Giaccone, G., Manegold, C., & van Meerbeeck, J. V. (2004) · Lung Cancer · doi:10.1016/s0169-5002(03)00292-7 · Cited by 126
Self-citationPemetrexed in Malignant Pleural Mesothelioma
Hazarika, M., White, R. M., Booth, B. P., Wang, Y.-C., Lee-Ham, D. Y., Liang, C. Y., Rahman, A., Gobburu, J. V. S., Li, N., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.982.11.3 · Cited by 108
Bottomley, A., Efficace, F., Thomas, R., Vanvoorden, V., & Ahmedzai, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.203 · Cited by 82
Self-citationvan Meerbeeck, J. P., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H. J. M., Pinson, P., Glabbeke, M. M. V., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.465 · Cited by 81
Self-citationMattson, K. V., Giaccone, G., Kirkpatrick, A., Evrard, D., Tammilehto, L., van Breukelen, F. J. M., Planteydt, H. T., & van Zandwijk, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.824 · Cited by 61
Self-citationThe activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma
Baas, P., Ardizzoni, A., Grossi, F., Nackaerts, K. L., Numico, G., Marck, E. V., van de Vijver, M. J., Monetti, F., Smid-Geirnaerdt, M. J. A., van Zandwijk, N., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00668-8 · Cited by 58
Self-citationSahmoud, T., Postmus, P. E., van Pottelsberghe, C., Mattson, K. V., Tammilehto, L., Splinter, T. A. W., Planting, A. S. T., Sutedja, T. G., von Pawel, J., van Zandwijk, N., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00183-4 · Cited by 48
Self-citationA phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
van Meerbeeck, J. P., Baas, P., Debruyne, C., Smit, E. F., van Klaveren, R. J., Galdermans, D., Lentz, M. A., Manegold, C., & Giaccone, G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00428-2 · Cited by 34
Self-citationPathology of malignant mesothelioma
Marck, E. V. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.04.006 · Cited by 15
Cited by
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00063109 · Cited by 638
Self-citationFlores, R. M., Pass, H. I., Seshan, V. E., Dycoco, J., Zakowski, M., Carbone, M., Bains, M. S., & Rusch, V. W. (2008) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.054 · Cited by 617
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Kindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420
Metadata
- Authors
- van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-01
- Volume
- 23
- Issue
- 28
- Pages
- 6881-6889
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2129967236
- Cited by
- 617
- References
- 31
- FWCI
- 31.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.